Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma
|dc.contributor.author||De Klerk, N.|
|dc.identifier.citation||Creaney, J. and Olsen, N. and Brims, F. and Dick, I. and Musk, A. and De Klerk, N. and Skates, S. et al. 2010. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiology Biomarkers and Prevention. 19 (9): pp. 2238-2246.|
Background: Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos. Since the recent discovery that serum mesothelin is a sensitive and highly specific biomarker for mesothelioma, one of the key issues raised is whether mesothelin levels represent a useful screening test for asbestos-exposed at-risk individuals. In this study, soluble mesothelin was determined in sequential serum samples collected from asbestos-exposed individuals before the development of mesothelioma. Methods: Archival serum samples from 106 individuals who developed mesothelioma, 99 asbestosexposed individuals from the Wittenoom Cancer Surveillance Program, and 109 non-asbestos-exposed individuals from the Busselton Health Survey were identified. Serum mesothelin concentrations were determined using the MESOMARK assay. Results: Longitudinal mesothelin levels determined in healthy asbestos-exposed individuals over a period of 4 years were stable (Pearson's r = 0.96; P < 0.0001). There was no correlation between mesothelin concentration and cumulative asbestos exposure. Mesothelin concentrations were greater than the threshold value of 2.5 nmol/L in the penultimate serum sample before the diagnosis of mesothelioma in 17 of 106 people. Using an increase above the 95% confidence interval of the mean of a given individual's longitudinal mesothelin results, 33 of 82 individuals had increasing mesothelin levels before diagnosis. Conclusion: In a population with a high pretest probability of developing mesothelioma, the serum biomarker mesothelin is elevated in absolute terms in 15% and in relative terms in 40% of the group. Impact: Future studies examining a combination of biomarkers could improve sensitivity of screening. ©2010 AACR.
|dc.publisher||American Association for Cancer Research Inc|
|dc.title||Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma|
|dcterms.source.title||Cancer Epidemiology Biomarkers and Prevention|
|curtin.department||Curtin Medical School|
|curtin.accessStatus||Open access via publisher|
Files in this item
There are no files associated with this item.